Cargando…
EGFR突变非小细胞肺癌免疫治疗相关研究进展
Targeted therapy and immunotherapy are important treatments for non-small cell lung cancer (NSCLC). At present, the clinical and basic research of epidermal growth factor receptor (EGFR) mutation NSCLC is still in the exploratory stage, needing to optimize the efficacy, combination, sequence and dos...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717865/ https://www.ncbi.nlm.nih.gov/pubmed/31451147 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.08.11 |
| _version_ | 1783447630354841600 |
|---|---|
| collection | PubMed |
| description | Targeted therapy and immunotherapy are important treatments for non-small cell lung cancer (NSCLC). At present, the clinical and basic research of epidermal growth factor receptor (EGFR) mutation NSCLC is still in the exploratory stage, needing to optimize the efficacy, combination, sequence and dosage of immunotherapy and other treatments, to clarify the relationship between EGFR mutation, immune microenvironment and the efficacy of immunotherapy. In this review, we summarized the newly updated data about immunotherapy in EGFR mutant NSCLC in term of pre-clinical study, programmed cell death protein ligand 1 (PD-L1) expression, tumor mutation burden and treatment. |
| format | Online Article Text |
| id | pubmed-6717865 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67178652019-09-02 EGFR突变非小细胞肺癌免疫治疗相关研究进展 Zhongguo Fei Ai Za Zhi 综述 Targeted therapy and immunotherapy are important treatments for non-small cell lung cancer (NSCLC). At present, the clinical and basic research of epidermal growth factor receptor (EGFR) mutation NSCLC is still in the exploratory stage, needing to optimize the efficacy, combination, sequence and dosage of immunotherapy and other treatments, to clarify the relationship between EGFR mutation, immune microenvironment and the efficacy of immunotherapy. In this review, we summarized the newly updated data about immunotherapy in EGFR mutant NSCLC in term of pre-clinical study, programmed cell death protein ligand 1 (PD-L1) expression, tumor mutation burden and treatment. 中国肺癌杂志编辑部 2019-08-20 /pmc/articles/PMC6717865/ /pubmed/31451147 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.08.11 Text en 版权所有©《中国肺癌杂志》编辑部2019 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
| spellingShingle | 综述 EGFR突变非小细胞肺癌免疫治疗相关研究进展 |
| title | EGFR突变非小细胞肺癌免疫治疗相关研究进展 |
| title_full | EGFR突变非小细胞肺癌免疫治疗相关研究进展 |
| title_fullStr | EGFR突变非小细胞肺癌免疫治疗相关研究进展 |
| title_full_unstemmed | EGFR突变非小细胞肺癌免疫治疗相关研究进展 |
| title_short | EGFR突变非小细胞肺癌免疫治疗相关研究进展 |
| title_sort | egfr突变非小细胞肺癌免疫治疗相关研究进展 |
| topic | 综述 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717865/ https://www.ncbi.nlm.nih.gov/pubmed/31451147 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.08.11 |
| work_keys_str_mv | AT egfrtūbiànfēixiǎoxìbāofèiáimiǎnyìzhìliáoxiāngguānyánjiūjìnzhǎn AT egfrtūbiànfēixiǎoxìbāofèiáimiǎnyìzhìliáoxiāngguānyánjiūjìnzhǎn |